FrancophonIA/ELRC3.0 huggingface dataset:
English: There is no consensus on the role of SYSADOA in the pharmacological treatment of OA.
Slovenian: Mnenja o tem, kakšna je vloga simptomatskega počasi delujočega zdravila za osteoartritis pri farmakološkem zdravljenju OA, so deljena.
English: With regards to the risk of gastrointestinal disorders, diarrhoea was a common and expected reaction of diacerein.
Slovenian: Kar zadeva tveganje za bolezni prebavil, je bila pogost in pričakovan neželen učinek diacereina driska.
English: In addition, given the gastrointestinal risk and potential risk of hepatic reactions, the PRAC considered limiting prescription by specialists experienced in the treatment of osteoarthritis.
Slovenian: Poleg tega je odbor PRAC ob upoštevanju tveganja za bolezni prebavil in možnega tveganja za jetrne reakcije obravnaval omejitev predpisovanja zdravila na specialiste, ki imajo izkušnje z zdravljenjem osteoartritisa.
English: It was noted that favourable results for the primary criterion, analogue visual scale (VAS) assessment of pain on movement, were shown in patients treated with 50mg/day.
Slovenian: Ugotovljeno je bilo, da so pri bolnikih, zdravljenih z odmerkom 50 mg/dan, zabeležili ugodne rezultate po glavnem merilu, ki je bila ocena bolečine pri gibanju na vizualni analogni lestvici (VAS).
English: Finally, several double-blind randomised clinical trials analysed the alleged NSAID sparing effect of diacerein as a secondary endpoint.
Slovenian: V nekaj dvojno slepih naključnih kliničnih preskušanjih so analizirali tudi domneven vpliv diacereina na zmanjšanje potrebe po uporabi nesteroidnih protivnetnih zdravil (sekundarna končna točka).
English: The structure-modifying effects of diacerein have also been assessed in few studies as well as its NSAIDs sparing effect (secondary endpoint).
Slovenian: V nekaj študijah so ocenili tudi vpliv diacereina na strukturne spremembe in zmanjšanje potrebe po uporabi nesteroidnih protivnetnih zdravil (sekundarna končna točka).
English: Finally, information on the cutaneous risk in the Summary of Product Characteristics (SmPC) was considered necessary.
Slovenian: Nenazadnje je treba v povzetek glavnih značilnosti zdravila vključiti informacije o tveganju za kožne reakcije;
English: Package Leaflet (PL) to better reflect the PRAC recommendations and to correct minor discrepancies.
Slovenian: Vendar pa je menila, da so potrebne določene spremembe v povzetku glavnih značilnosti zdravila in navodilu za uporabo, da bi bila vsebina skladnejša s priporočili odbora PRAC in da bi odpravili manjša odstopanja.
English: Pain and functional disability of the affected joints are the main manifestations of osteoarthritis.
Slovenian: Glavna simptoma osteoartritisa sta bolečina in funkcionalna prizadetost sklepov.
English: The recommended starting dose is three tablets once daily and can be increased to 5 tablets once daily after 4 weeks depending on the patient's response.
Slovenian: Priporočeni začetni odmerek je tri tablete enkrat na dan in se lahko po štirih tednih poveča na pet tablet enkrat na dan, kar je odvisno od bolnikovega odziva.
English: Treatment should continue for as long as the patient benefits from it.
Slovenian: Zdravljenje je treba nadaljevati tako dolgo, dokler je za bolnika koristno.
English: What measures are being taken to ensure the safe and effective use of Xospata?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Xospata?
English: The European Medicines Agency therefore decided that Xospata's benefits are greater than its risks and it can be authorised for use in the EU.
Slovenian: Evropska agencija za zdravila je zato zaključila, da so koristi zdravila Xospata večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
English: Other information about Xospata
Slovenian: Druge informacije o zdravilu Xospata
English: If certain side effects develop, the doctor may decide to reduce the dose or stop the treatment intermittently or entirely.
Slovenian: Če se pojavijo določeni neželeni učinki, se lahko zdravnik odloči, da bo zmanjšal odmerek ali začasno oziroma dokončno prekinil zdravljenje.
English: Further information on the orphan designation can be found here: ema.europa.eu/medicines/human/orphan-designations/eu3171961.
Slovenian: Nadaljnje informacije glede določitve zdravila sirote lahko najdete tukaj: ema.europa.eu/medicines/human/orphan-designations/eu3171961
English: Xospata is available as tablets (40 mg).
Slovenian: Zdravilo Xospata je na voljo v obliki tablet (40 mg).
English: Patients receiving Xospata lived on average 9.3 months compared with 5.6 months for those receiving various types of chemotherapy.
Slovenian: Bolniki, ki so prejemali zdravilo Xospata, so v povprečju živeli 9,3 meseca v primerjavi s 5,6 meseca pri tistih, ki so prejemali različne vrste kemoterapije.
English: Patients will also receive a patient card with information on when to seek medical advice if differentiation syndrome is suspected.
Slovenian: Bolniki bodo prejeli tudi kartico za bolnike z informacijami o tem, kdaj poiskati zdravniško pomoč, če obstaja sum na sindrom diferenciacije.
English: As for all medicines, data on the use of Xospata are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Xospata stalno spremljajo.
English: Before starting treatment, doctors will use a genetic test to confirm that the patient has an FLT3 mutation.
Slovenian: Pred začetkom zdravljenja bodo zdravniki opravili genetsko testiranje, da potrdijo, da ima bolnik mutacijo FLT3.
English: What benefits of Xospata have been shown in studies?
Slovenian: Kakšne koristi zdravila Xospata so se pokazale v študijah?
English: An overview of Xospata and why it is authorised in the EU
Slovenian: Pregled zdravila Xospata in zakaj je odobreno v EU
English: Side effects reported with Xospata are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Xospata, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: The company that markets Xospata will provide educational materials to healthcare professionals and patients about the signs and symptoms of differentiation syndrome.
Slovenian: Podjetje, ki trži zdravilo Xospata, bo zdravstvenim delavcem in bolnikom zagotovilo izobraževalno gradivo o znakih in simptomih sindroma diferenciacije.
English: What is Xospata and what is it used for?
Slovenian: Kaj je zdravilo Xospata in za kaj se uporablja?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Xospata have also been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Xospata upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
English: Why is Xospata authorised in the EU?
Slovenian: Zakaj je bilo zdravilo Xospata odobreno v EU?
English: Other serious side effects include a disorder related to white blood cells known as differentiation syndrome, a brain condition known as posterior reversible encephalopathy syndrome (PRES) and heart rhythm problems.
Slovenian: Drugi resni neželeni učinki vključujejo motnjo, povezano z belimi krvnimi celicami, znano kot sindrom diferenciacije, tj. možgansko obolenje, imenovano sindrom posteriorne reverzibilne encefalopatije (PRES), in težave s srčnim ritmom.
English: Side effects with Xospata are those expected of this class of medicines and considered manageable.
Slovenian: Neželeni učinki zdravila Xospata so enaki tistim, ki se pričakujejo za ta razred zdravil, in veljajo za obvladljive.
English: For more information about using Xospata, see the package leaflet or contact your doctor or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Xospata glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: Xospata can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in using cancer medicines.
Slovenian: Predpisovanje in izdaja zdravila Xospata je le na recept, zdravljenje pa mora začeti in nadzorovati zdravnik, ki ima izkušnje z uporabo zdravil za zdravljenje raka.
English: The most common side effects with Xospata (which may affect more than 1 in 10 people) are increased levels of some enzymes in the blood (creatine phosphokinase, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase), diarrhoea, tiredness, nausea (feeling sick), constipation, cough, peripheral oedema (swelling, especially of the ankles and feet), dyspnoea (shortness of breath), dizziness, hypotension (low blood pressure), pain in the extremities, weakness, joint pain and muscle pain.
Slovenian: Najpogostejši neželeni učinki zdravila Xospata (ki se lahko pojavijo pri več kot 1 osebi od 10) so povečane ravni nekaterih encimov v krvi (kreatin-fosfokinaze, alanin-aminotransferaze, aspartataminotransferaze, alkalin-fosfataze), driska, utrujenost, navzeja (siljenje na bruhanje), zaprtje, kašelj, periferni edem (otekanje, zlasti gležnjev in stopal), dispneja (oteženo dihanje), omotica, hipotenzija (nizek krvni tlak), bolečine v okončinah, oslabelost, bolečine v sklepih in mišicah.
English: What are the risks associated with Xospata?
Slovenian: Kakšna tveganja so povezana z zdravilom Xospata?
English: Xospata was shown to prolong patients' lives in comparison to other cancer therapies.
Slovenian: Za zdravilo Xospata se je izkazalo, da podaljša življenje bolnikov v primerjavi z drugimi zdravili za zdravljenje raka.
English: The active substance in Xospata is gilteritinib.
Slovenian: Učinkovina v zdravilu Xospata je gilteritinib.
English: The active substance in Xospata, gilteritinib, blocks the action of enzymes known as tyrosine kinases, in particular a tyrosine kinase called FLT3 which normally controls growth and division of white blood cells.
Slovenian: Učinkovina v zdravilu Xospata, gilteritinib, zavira delovanje encimov, znanih kot tirozin kinaze, zlasti tirozin kinaze, imenovane FLT3, ki običajno nadzoruje rast in delitev belih krvnih celic.
English: The most common serious side effects (which may affect up to 1 in 10 people) are diarrhoea, increased levels of liver enzymes in the blood, dyspnoea and hypotension.
Slovenian: Najpogostejši resni neželeni učinki (ki se lahko pojavijo pri največ 1 osebi od 10) so driska, povišane ravni jetrnih encimov v krvi, dispneja in hipotenzija.
English: The doctor will also carry out regular blood tests and check the patient's heart function before and during treatment.
Slovenian: Zdravnik bo pred in med zdravljenjem v rednih intervalih pri bolniku izvajal krvne preiskave in preverjal delovanje njegovega srca.
English: In patients who have an FLT3 mutation, FLT3 is overactive and stimulates the growth of too many white blood cells.
Slovenian: Pri bolnikih z mutacijo FLT3 je FLT3 preveč dejaven in spodbuja rast prevelikega števila belih krvnih celic.
English: In a main study with 371 patients with AML who have an FLT3 mutation, and whose disease had come back or had not improved following previous treatment, Xospata prolonged patients' lives compared with patients receiving chemotherapy.
Slovenian: V glavni študiji, v kateri je sodelovalo 371 bolnikov z akutno mieloično levkemijo, ki imajo mutacijo FLT3 in katerih bolezen se je po predhodnem zdravljenju ponovila ali se ni izboljšala, je zdravilo Xospata podaljšalo življenje bolnikov v primerjavi z bolniki, ki so prejemali kemoterapijo.
English: Xospata is a cancer medicine used to treat adults with acute myeloid leukaemia (AML), a cancer of white blood cells.
Slovenian: Xospata je zdravilo za zdravljenje raka, ki se uporablja pri odraslih z akutno mieloično levkemijo (AML), tj. vrsto raka, ki prizadene bele krvne celice.
English: For the full list of side effects and restrictions of Xospata, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Xospata glejte navodilo za uporabo.
English: Patients with AML who have an FLT3 mutation, and whose disease has come back or has not improved following previous treatment, have a poor prognosis and treatment options are limited.
Slovenian: Bolniki z akutno mieloično levkemijo, ki imajo mutacijo FLT3 in katerih bolezen se je po predhodnem zdravljenju ponovila ali se ni izboljšala, imajo slabo prognozo in le omejene možnosti zdravljenja.
English: Further information on Xospata can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/xospata This overview was last updated in 10-2019.
Slovenian: Nadaljnje informacije o zdravilu Xospata so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/xospata
English: Xospata is used when AML has either come back or has not improved following previous treatment and is only given to patients whose cancer cells have a particular change (mutation) in the gene for a protein called FLT3.
Slovenian: Uporablja se, kadar se je akutna mieloična levkemija ponovila ali se ni izboljšala po predhodnem zdravljenju, pri čemer se lahko daje le bolnikom, katerih rakave celice imajo posebno spremembo (mutacijo) gena za beljakovino, imenovano FLT3.
English: AML is rare, and Xospata was designated an ‘orphan medicine' (a medicine used in rare diseases) on 17 January 2018.
Slovenian: Ker je akutna mieloična levkemija redka bolezen, je bilo zdravilo Xospata 17. januarja 2018 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni).
English: By blocking FLT3, gilteritinib is expected to stop white blood cell growth and thus slow down the development of the cancer.
Slovenian: Gilteritinib naj bi z zaviranjem FLT3 ustavil rast belih krvnih celic in tako upočasnil razvoj raka.
English: How does Xospata work?
Slovenian: Kako zdravilo Xospata deluje?
English: How is Xospata used?
Slovenian: Kako se zdravilo Xospata uporablja?
English: Xospata received a marketing authorisation valid throughout the EU on 24 October 2019.
Slovenian: Povzetek je bil nazadnje posodobljen 10-2019.
English: Date of opening:__________
Slovenian: Datum odprtja:____________
English: Date of first authorisation: 28 November 2011 Date of latest renewal: 16 August 2016
Slovenian: Datum prve odobritve: 28. november 2011 Datum zadnjega podaljšanja: 16. avgust 2016
English: Do not give this medicine to children less than 12 years of age.
Slovenian: Ne dajte tega zdravila otrokom, mlajšim od 12 let.
English: The tablet can be taken with or without food.
Slovenian: Tableto se lahko vzame s hrano ali brez nje.
English: If you forget to take your dose on time, take it as soon as possible and then go back to your regular dosing schedule.
Slovenian: Če ste pozabili vzeti odmerek pravočasno, ga vzemite čim prej in potem nadaljujte z ustaljenim režimom odmerjanja.
English: Shelf life after first opening of the tablet container: 3 months.
Slovenian: Rok uporabnosti po prvem odprtju vsebnika za tablete: 3 mesece.
English: 7 film-coated tablets: EU/1/11/739/001 10 film-coated tablets: EU/1/11/739/002 20 film-coated tablets: EU/1/11/739/003 30 film-coated tablets: EU/1/11/739/004 50 film-coated tablets: EU/1/11/739/005 90 film-coated tablets: EU/1/11/739/006 100 film-coated tablets: EU/1/11/739/007 250 film-coated tablets: EU/1/11/739/008
Slovenian: 7 filmsko obloženih tablet: EU/1/11/739/001 10 filmsko obloženih tablet: EU/1/11/739/002 20 filmsko obloženih tablet: EU/1/11/739/003 30 filmsko obloženih tablet: EU/1/11/739/004 50 filmsko obloženih tablet: EU/1/11/739/005 90 filmsko obloženih tablet: EU/1/11/739/006 100 filmsko obloženih tablet: EU/1/11/739/007 250 filmsko obloženih tablet: EU/1/11/739/008
English: and talc (E553b).
Slovenian: in smukec (E553b).
English: Adults and adolescents 12 years of age and over The recommended dose is one tablet once a day with water, with or without food.
Slovenian: Odrasli in mladostniki stari 12 let in več Priporočeni odmerek je ena tableta enkrat na dan z vodo, s hrano ali brez nje.
English: Pharmacotherapeutic group: Other antihistamines for systemic use, ATC code: R06AX27
Slovenian: Farmakoterapevtska skupina: drugi antihistaminiki za sistemsko zdravljenje, oznaka ATC: R06AX27
English: As a precautionary measure, it is preferable to avoid the use of desloratadine during pregnancy.
Slovenian: Iz previdnostnih razlogov se je med nosečnostjo uporabi desloratadina bolje izogibati.
English: - abnormal behaviour, - aggression, - weight increased, - increased appetite.
Slovenian: - nenormalno vedenje, - agresivnost - povečana telesna masa, - povečan tek.
English: A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from desloratadine therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Slovenian: Odločiti se je treba med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja z desloratadinom, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
English: For urticaria, the duration of treatment may be variable from patient to patient and therefore you should follow the instructions of your doctor.
Slovenian: Pri urtikariji se lahko potrebna dolžina zdravljenja razlikuje od bolnika do bolnika, zato upoštevajte navodila zdravnika.
English: Treatment with desloratadine also significantly reduced interference with sleep and daytime function, as measured by a four-point scale used to assess these variables.
Slovenian: Zdravljenje z desloratadinom je tudi bistveno zmanjšalo motnje spanja in dnevnih dejavnosti bolnika, kar so ugotavljali na podlagi meritev s štiritočkovno lestvico za oceno teh spremenljivk.
English: Other medicines and Dasselta
Slovenian: Druga zdravila in zdravilo Dasselta
English: Do not use this medicine after the expiry date which is stated on the packaging after EXP.
Slovenian: Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na ovojnini poleg oznake »EXP:«.
English: The efficacy of desloratadine tablets has not been clearly demonstrated in trials with adolescent patients 12 through 17 years of age.
Slovenian: Učinkovitosti tablet z desloratadinom niso jasno dokazali v preskušanjih pri mladostnikih, starih od 12 do 17 let.
English: Do not take Dasselta - if you are allergic to desloratadine, to any of the other ingredients of this medicine (listed in section 6) or to loratadine.
Slovenian: Ne jemljite zdravila Dasselta - če ste alergični na desloratadin, katero koli sestavino tega zdravila (navedeno v poglavju 6) ali loratadin.
English: for tablet container:
Slovenian: za vsebnik za tablete:
English: Regarding the duration of treatment, your doctor will determine the type of allergic rhinitis you are suffering from and will determine for how long you should take Dasselta.
Slovenian: Kar zadeva trajanje zdravljenja, bo vaš zdravnik najprej ugotovil vrsto alergijskega rinitisa, ki jo imate, in na podlagi tega določil, kako dolgo naj bi jemali zdravilo Dasselta.
English: If you forget to take Dasselta
Slovenian: Če ste pozabili vzeti zdravilo Dasselta
English: Blister (OPA/Alu/PVC//Alu): 7, 10, 20, 30, 50, 90 and 100 film-coated tablets, in a box.
Slovenian: Pretisni omot (OPA/Al/PVC//Al): 7, 10, 20, 30, 50, 90 in 100 filmsko obloženih tablet, v škatli.
English: What you need to know before you take Dasselta
Slovenian: Kaj morate vedeti, preden boste vzeli zdravilo Dasselta
English: Excipient: lactose monohydrate.
Slovenian: Pomožna snov: laktoza monohidrat.
English: Very rare (the following may affect up to 1 in 10,000 people): - severe allergic reactions, - rash, - pounding or irregular heartbeat, - fast heartbeat, - stomach ache, - feeling sick (nausea), - vomiting, - upset stomach, - diarrhoea, - dizziness, - drowsiness, - inability to sleep, - muscle pain, - hallucinations, - seizures, - restlessness with increased body movement, - liver inflammation, - abnormal liver function tests.
Slovenian: Zelo redki (naslednji se lahko pojavijo pri največ 1 od 10.000 bolnikov): - hude alergijske reakcije, - izpuščaj, - razbijanje srca ali nereden srčni utrip, - hitro bitje srca, - bolečine v želodcu, - občutek slabosti (siljenje na bruhanje), - bruhanje, - razdražen želodec, - driska, - omotica, - zaspanost, - nezmožnost spanja, - bolečine v mišicah, - halucinacije, - epileptični napadi, - nemir z okrepljenimi telesnimi gibi, - vnetje jeter, - nenormalni izvidi preiskav delovanja jeter.
English: Hypersensitivity to the active substance, to any of the excipients listed in section 6.1 or to loratadine.
Slovenian: Preobčutljivost na učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1 ali na loratadin.
English: Excipient with known effect: Each film-coated tablet contains 16.15 mg lactose (as monohydrate).
Slovenian: Pomožna snov z znanim učinkom: Ena filmsko obložena tableta vsebuje 16,15 mg laktoze (v obliki monohidrata).
English: The enzyme responsible for the metabolism of desloratadine has not been identified yet, and therefore, some interactions with other medicinal products can not be fully excluded.
Slovenian: Encima, ki je odgovoren za presnovo desloratadina, še niso določili, zato ni mogoče v celoti izključiti nekaterih interakcij desloratadina z drugimi zdravili.
English: Light blue, round, film-coated tablets with beveled edges (diameter: 6.5 mm, thickness: 2.3-3.5 mm).
Slovenian: Svetlo modre, okrogle, filmsko obložene tablete s prirezanimi robovi (premer: 6,5 mm, debelina: 2,33,5 mm).
English: Other undesirable effects reported during the post-marketing period in paediatric patients with an unknown frequency included QT prolongation, arrhythmia, bradycardia, abnormal behaviour and aggression.
Slovenian: Ostali neželeni učinki, o katerih so poročali v obdobju trženja zdravila pri pediatričnih bolnikih z neznano pogostnostjo, vključujejo podaljšanje QT intervala, aritmijo, bradikardijo, nenormalno vedenje in agresivnost.
English: There are no known interactions of Dasselta with other medicines.
Slovenian: Ni znanih interakcij med zdravilom Dasselta in drugimi zdravili.
English: Tablet container (HDPE, volume 60 ml), PP closure with desiccant: 250 film-coated tablets, in a box.
Slovenian: Vsebnik za tablete (HDPE, volumen 60 ml), PP zaporka s sušilnim sredstvom: 250 filmsko obloženih tablet, v škatli.
English: Not known: frequency cannot be estimated from the available data - slow heartbeat, - change in the way the heart beats, - abnormal behaviour, - aggression.
Slovenian: Neznana pogostnost (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti): - počasen srčni utrip, - sprememba v načinu bitja srca, - nenormalno vedenje, - agresivnost.
English: 7 film-coated tablets 10 film-coated tablets 20 film-coated tablets 30 film-coated tablets 50 film-coated tablets 90 film-coated tablets 100 film-coated tablets for tablet container: 250 film-coated tablets
Slovenian: 7 filmsko obloženih tablet 10 filmsko obloženih tablet 20 filmsko obloženih tablet 30 filmsko obloženih tablet 50 filmsko obloženih tablet 90 filmsko obloženih tablet 100 filmsko obloženih tablet za vsebnik za tablete: 250 filmsko obloženih tablet
English: Adults and adolescents (12 years of age and over) The recommended dose of Dasselta is one tablet once a day.
Slovenian: Odrasli in mladostniki (stari 12 let ali več) Priporočeni odmerek zdravila Dasselta je ena tableta enkrat na dan.
English: Each film-coated tablet contains 5 mg desloratadine.
Slovenian: Ena filmsko obložena tableta vsebuje 5 mg desloratadina.
English: In clinical studies with desloratadine, the following side effects were reported as:
Slovenian: V kliničnih študijah z desloratadinom so poročali o naslednjih neželenih učinkih:
English: Dasselta is also used to relieve the symptoms associated with urticaria (a skin condition caused by an allergy).
Slovenian: Zdravilo Dasselta se uporablja tudi za lajšanje simptomov urtikarije (težave s kožo zaradi alergije).
English: Common (the following may affect up to 1 in 10 people): - fatigue, - dry mouth, - headache.
Slovenian: Pogosti: naslednji se lahko pojavijo pri največ 1 od 10 bolnikov - utrujenost, - suha usta, - glavobol.